tual results to differ materially. Some of the specific factors that could cause BioLife Solutions' actual results to differ materially are discussed in the Company's recent filings with the Securities and Exchange Commission. BioLife Solutions disclaims any obligation to update any forward-looking statements as a result of developments occurring after the date of this press release. Media Relations:Investor Relations:Len Hall
Matt ClawsonAllen & Caron Inc
Allen & Caron Inc(949) 474-4300
(949) 474-4300len@allencaron.com
matt@allencaron.com BioLife Solutions, Inc.Statement of OperationsThree MonthsEnded September 30,Nine MonthsEnded September 30,2012201120122011RevenueProduct sales
$
1,676,480$
710,518$
3,599,770$
1,934,165Licensing revenue5,0005,00015,00015,000Total revenue1,681,480715,5183,614,7701,949,165Cost of product sales1,086,031345,5562.073,9091,003,071Gross profit595,449369,9621,540,861946,094Operating expensesResearch and development110,68998,903353,837391,086Sales and marketing145,73555,443379,774197,883General and administrative487,733500,4241,441,8521,356,222Total operating expenses744,157654,7702,175,4631,945,191Operating loss(148,708)(284,808)(634,602)(999,097)Other income (expenses)Other income ––2094,25343Interest expense(185,554)(171,677)(547,875)(497,458)Gain (loss) on disposal of equipment431(1,896)368(1,896)Amortization of deferred financing costs(18,397)(20,307)(60,142)(47,061)Total other income (expenses)(203,520)(193,860)(513,396)(546,372)Net Loss
$
(352,228)$
(478,668)$
(1,147,998)$
(1,545,469)Basic and diluted net loss per common share
$
(0.01)$
(0.01)$
(0.02)$
(0.02)Basic and diluted weighted average common shares used to calculate net loss per common sha
'/>"/>
SOURCE BioLife Solutions, Inc. Copyright©2012 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 Related biology technology :1.
BioLife Solutions Launches Search Engine Optimized Website and 1,000 Free Samples Offer2.
BioLife Solutions 2011 Revenue Up 33%3.
BioLife Solutions Adds Clinical and Commercialization Experts to Scientific Advisory Board4.
Improved Cord Blood Processing Research on BioLife Solutions CryoStor® Published in TRANSFUSION5.
BioLife Solutions Completes Corporate Facilities Expansion, Build-Out of Additional cGMP Clean Room Manufacturing Suite6.
BioLife Solutions Announces 2012 Second Quarter Results: Eighth Straight Quarter of Record Revenue7.
BioLife Solutions Announces Presentation at IBC Inaugural Cell Therapy Clinical Development Conference8.
Chandler Chicco Companies Acquires Haas & Health Partner Public Relations and SanCom Creative Communication Solutions, Creating Unrivalled Healthcare Communication Capability in Germany9.
ZyGEM and USAMRIID Sign CRADA for Development of Simplified Sample Processing Solutions for Biothreat Agents10.
Elsevier Acquires QUOSA, Provider of Life Sciences Content Management and Workflow Productivity Solutions11.
Dyadic International Partners with Leading Provider of Nutritional Ingredient Solutions for Production of Food Enzymes